## **Potassium Binders**

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

## **POS Abbreviations**

AL – Age Limit	DS – Maximum Days' Supply Allowed	PU – Prior Use of Other Medication is Required
<b>BH</b> – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	<b>DT</b> – Duration of Therapy Limit	QL – Quantity Limit
<b>BY</b> – Diagnosis Codes Bypass Some Requirements	<b>DX</b> – Diagnosis Code Requirement	RX – Specific Prescription Requirement
CL – Additional Clinical Information is Required	ER – Early Refill	<b>TD</b> – Therapeutic Duplication
CU – Concurrent Use with Other Medication is Restricted	MD – Maximum Dose Limit	YQ – Yearly Quantity Limit
<b>DD</b> – Drug-Drug Interaction	MME – Maximum Morphine Milligram Equivalent is Restricted	

## **Potassium Binders**

POS Edits				
CL – Additional clinical information (prescriber specialty, diagnosis, etc.) is required for patiromer (Veltassa®).				
QL – Patiromer (Veltassa®) is limited to athe	Packet Strength	Quantity Limit		
maximumhas a quantity listed in the table to the	<u>1 gm</u>	4 packets per day		
right.limit of 30 packets per 30 days.	8.4 gm, 16.8 gm, 25.2 gm	1 packet per day		

Revision / Date	Implementation Date	
Created POS Document	July 2021	
Removed clinical authorization requirement for Lokelma / May 2023	July 2023	
Modified quantity limits for Veltassa® to include new strength / March 2025	<u>August 2025</u>	